AbCellera founder and CEO Carl Hansen (L) and Rallybio CEO Martin Mackay

Rally­bio, Ab­Cellera form new part­ner­ship around an­ti­bod­ies for rare dis­ease

Two biotechs that have been work­ing heav­i­ly on dif­fer­ent stages of an­ti­body can­di­date de­vel­op­ment over the past sev­er­al years are look­ing to work to­geth­er to find po­ten­tial can­di­dates for rare dis­eases.

Cana­di­an-based Ab­Cellera and Con­necti­cut-based Rally­bio have en­tered a strate­gic part­ner­ship to find, de­vel­op and com­mer­cial­ize an­ti­bod­ies pri­mar­i­ly for rare dis­eases. The mul­ti-year, mul­ti-tar­get deal will seek to com­bine Ab­Cellera’s an­ti­body “dis­cov­ery en­gine” with Rally­bio’s ex­per­tise in rare dis­eases. How­ev­er, the dol­lar amount for the deal was not dis­closed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA